NLRP3 and COVID-19: Finally, new therapies based on avoiding NETosis, blocking inflammation mediated by NLRP3 inflammasome, or blocking the pathway activated through L-SIGN, could also be feasible strategies to improve critical characteristics related to COVID-19 [101,115].